How TRUMENBA WorksTRUMENBA targets a gene found in >99% of invasive MenB disease strains1,2TRUMENBA works by targeting both subfamilies, A and B, of a lipoprotein—factor H binding protein (fHbp)—for which the gene is found in more than 99% of invasive MenB strains.1,2
The fHbp DiscoveryPfizer used a combined biochemical and immunological screening approach to identify surface-expressed proteins on MenB strains that were capable of inducing antibodies that could kill diverse meningococcal strains. During this process, fHbp elicited robust bactericidal responses.1
From 2011 through 2019MenB strains expressing fHbp subfamilies A and B have caused disease outbreaks at colleges such as Providence College, Rutgers University, UC Santa Barbara, and University of Oregon.5-7
Contact your Pfizer Sales Representative or call a Vaccine Specialist at 1-800-666-7248.ReferencesBased on demonstrated effectiveness against 14 diverse strains representative of prevalent MenB strains.1References:1. TRUMENBA [package insert]. Philadelphia, PA: Pfizer Inc.; 2021. 2. Murphy E, Andrew L, Lee KL, et al. Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis. J Infect Dis. 2009;200(3):379-389. 3. Wang X, Cohn A, Comanducci M, et al. Prevalence and genetic diversity of candidate vaccine antigens among invasive Neisseria meningitidis isolates in the United States. Vaccine. 2011;29(29-30):4739-4744. 4. Harris SL, Donald RGK, Hawkins JC, et al. Neisseria meningitidis serogroup B vaccine, bivalent rLP2086, induces broad serum bactericidal activity against diverse invasive disease strains including outbreak strains. Pediatr Infect Dis J. 2017;36(2):216-223. 5. Soeters HM, Dinitz-Sklar J, Kulkarni PA, et al. Serogroup B meningococcal disease vaccine recommendations at a university, New Jersey, USA, 2016. Emerg Infect Dis. 2017;23(5):867-869. 6. Soeters HM, McNamara LA, Whaley M, et al. Serogroup B meningococcal disease outbreak and carriage evaluation at a college—Rhode Island, 2015. MMWR Morb Mortal Wkly Rep. 2015;64(22):606-607. 7. Data on file. Meningitis case outbreaks. Pfizer Inc., New York, NY. 8. Tully J, Viner RM, Coen PG, et al. Risk and protective factors for meningococcal disease in adolescents: matched cohort study. BMJ. 2006;332(7539):445-450. 9. Centers for Disease Control and Prevention. Meningococcal disease. Centers for Disease Control and Prevention website. Updated January 21, 2020. Accessed April 1, 2021. http://www.cdc.gov/meningococcal/index.html. 10. Dwilow R, Fanella S. Invasive meningococcal disease in the 21st century—an update for the clinician. Curr Neurol Neurosci Rep. 2015;15(2):1-9. 11. Balmer P, Burman C, Serra L, York LJ. Impact of meningococcal vaccination on carriage and disease transmission: a review of the literature. Hum Vaccin Immunother. 2018;14(5):1118-1130. 12. Mbaeyi SA, Bozio CH, Duffy J, et al. Meningococcal vaccination: recommendations of the Advisory Committee on Immunization Practices, United States, 2020. MMWR Recomm Rep. 2020;69(9):1-41.